Efficacy of Majoon Rasheedi in Benign Prostatic Hyperplasia: A Case Report
Abstract
Benign prostatic hyperplasia is a prevalent urological disorder in older men, primarily presenting as lower urinary tract symptoms. A majority of BPH may remain asymptomatic. By 2019, the prevalence of BPH rose to approximately 94 million men, compared to 51.1 million in 2000. Conventional treatments, including alpha-blockers and procedures like transurethral resection of the prostate, effectively alleviate symptoms but frequently entail adverse effects. The Unani system of medicine offers an alternative approach to managing BPH, classifying it as waram unuq al-mathāna (swelling of the bladder neck), with an underlying barid (cold) temperament associated with the accumulation of morbid phlegm. A 66-year-old male presented with symptoms, including frequent urination (12-15/day), weak urinary stream, urgency, and post-void dribbling. He was previously treated with allopathic medication without any symptomatic improvement and was advised to undergo surgery. Ultrasound imaging revealed an enlarged prostate (46 cc in volume) and a post-void residual urine volume of 416 cc. The patient received Majoon Rasheedi, a Unani formulation used for BPH for 45 days. The prostate volume reduced from 46 cc to 36 cc, while the post-void residual urine volume declined from 416 cc to 230 cc. His International Prostate Symptom Score improved significantly, dropping from 26 to 6, while the peak urinary flow rate increased from 10 ml/s to 13 ml/s, reflecting improved urinary function. This case…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health. Reported size: 94 participants or records.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.